1. Contracts ending soon
  2. Office of Assistant Secretary for Preparedness and Response
  3. NAICS 541714

Research and Development in Biotechnology (except Nanobiotechnology) contracts ending at Office of Assistant Secretary for Preparedness and Response

Department of Health and Human Services

62 contracts of $100,000 or more under NAICS 541714, research and development in biotechnology (except nanobiotechnology), at Office of Assistant Secretary for Preparedness and Response end in the next 18 months, with $1.28B obligated so far. 18 end within six months, so their follow-on may already be in the works.

Ending in 18 months
62 contracts$1.28B obligated so far
Biggest holder
Advanced Technology International$261M on 2 contracts ending soon
Open notices
NAICS 541714contract opportunities open now
Source
USAspending.govUpdated Nov 17, 2026, 7:37 PM UTC

Contracts ending soon

Soonest end first. Each contract links to its record on USAspending.gov.

ContractObligatedEndsState
Capture Bioscience, Inc. R&D for Beads by Time-of-Flight. Isotope-Based Technology Enabling Highly Scalable Multiplex Serology. Area of Interest No: #23 (Host-Based Diagnostics)Capture Bioscience Inc. · 75A50124C00037$749,999Nov 30, 2026within a monthCA
MACH32- Development of Intramuscular Tranexamic Acid FormulationMACH32 Inc · 75A50124C00058$749,846Nov 30, 2026within a monthNot stated
Vaxxas - Development of Hd-Micro Array Patch (Map) to Deliver a Vaccine Against a Pandemic Strain of Influenza, H5N1.Vaxxas Pty Ltd · 75A50120C00180$29,594,472Dec 30, 2026in 1 monthNot stated
Clinical Development of Crispr-CAS3 Phage Cocktail for the Treatment of Recurrent Urinary Tract Infections Caused by Escherichia Coli Including Antimicrobial and Multi-Drug Resistant StrainsLocus Biosciences Inc · 75A50120C00169$73,885,104Dec 31, 2026in 1 monthNC
This Acquisition Will Allow Barda to Invest Project Bioshield Funds for Late-Stage Clinical Development, Regulatory Approval for 2-Pam Autoinjectors (As a Drug/Device Combination Product) to Treat…Aktivax, Inc. · 75A50122C00082$45,323,792Dec 31, 2026in 1 monthCO
Enalare Therapeutics: an Agnostic Respiratory Stimulant for Use As a Medical Countermeasure to Treat Respiratory DepressionEnalare Therapeutics Inc · 75A50122C00072$12,209,278Dec 31, 2026in 1 monthNJ
The Purpose of This Task Order Is to Procure a Influenza a(H2NX) Virus Vaccine Candidate(S) and Conduct Clinical TrialSeqirus Inc · 75A50121F33010$21,404,610Jan 31, 2027in 2 monthsNC
The Objection of This Task Order Is to Evaluate Inbios? Aad Plus Device (Lateral Flow Test) Ability to Detect Lf and Ltx in Capillary and Venous Blood From Nonhuman Primates After an Inhalation…Battelle Memorial Institute · 75A50125F61009$1,391,049Jan 31, 2027in 2 monthsOH
This Task Order Establishes Services for H5 Pandemic Readiness for Acquisition of Medical Countermeasures (Mcms) for Pandemic Influenza and Emerging Diseases Preparedness and Response Under Contract…Glaxosmithkline, LLC · 75A50124F61014$18,193,095Feb 21, 2027in 3 monthsNC
The Purpose of This Task Order Is to Establish Fill/Finish Activities for Adjuvant (AS03) to Support the Covid-19 Federal Response- Multi-Dose Vials for HHS Under Idiq Contract #75A50122D00002.Glaxosmithkline, LLC · 75A50124F61013$15,411,200Feb 21, 2027in 3 monthsNC
The Overall Objective of This Contract Is to Identify Humoral Correlates of Protection Following H3N2 M2SR Vaccination, Supporting the Clinical Development of M2SR As a Strategy to Induce Both…Flugen Inc · 75A50125C00005$741,722Feb 28, 2027in 3 monthsWI
Development of a Low-Cost, Point-of-Need Molecular Test for Flu A+b and Self-Collected Swab Specimens.Sherlock Biosciences, Inc. · 75A50124C00055$3,079,315Mar 1, 2027in 3 monthsMA
Genomic Sequencing of Sars-COV2 VariantsBioinfoexperts LLC · 75A50123P00017$4,283,031Mar 26, 2027in 4 monthsLA
Use of a Human-Relevant Small Animal Model of Sulfur Mustard (Sm)-Induced Inhalation Injuries to Screen Potential Medical Countermeasures (Mcms)Battelle Memorial Institute · 75A50125F61004$7,565,998Mar 28, 2027in 4 monthsDC
Oxivax - Aoi #28: Influenza Vaccine Innovation. Advancing Metagenomic Next-Generation Sequencing Based Agnostic Diagnostics for Viral Pathogens the Overall Objective of This Contract Is to Prepare…Osivax · 75A50125C00006$743,969Mar 31, 2027in 4 monthsNot stated
Research and Development- Aoi #16+ Seeking to Manufacture and Obtain Regulatory Approval for the Cytotracker Bv, a Point-of-Care Instant White Blood Cell Analysis Platform for Discriminating Between…Rizlab Health Inc · 75A50123C00028$2,483,472Apr 10, 2027in 4 monthsNJ
Radnuc 2201: Performance Verification of Institutional Radiation Dose Response for Acute Radiation Syndrome (Ars) Animal Models (Rodent, Rabbit, Minipig, or Non-Human Primate [nhp])Lovelace Biomedical Research Institute · 75A50123F61001$5,905,018Apr 17, 2027in 5 monthsNM
Memed Diagnostics- the R&D Effort to Demonstrate Clinical Utility of Memed Bv, Rapid Host-Based Diagnostic (Hbd) for Distinguishing Bacterial Vs Viral InfectionMemed Diagnostics Ltd · 75A50123C00041$727,799Apr 30, 2027in 5 monthsNot stated
The Purpose of This HHS Task Order Is to Procure Services for the Storage and Stability of Bulk Lots & Final Containers of-Adjuvant( AS03) Covid-19 Funds.Glaxosmithkline, LLC · 75A50124F61012$14,047,404May 21, 2027in 6 monthsNC
The Purpose of This Requirement Is to Provide Medical Countermeasures (Mcms), Such As Vaccines and Adjuvants, for Pandemic Preparedness and Response or As Required in Response to a HHS DesignatedSanofi Vaccines US Inc. · 75A50124F61008$12,577,341May 21, 2027in 6 monthsPA
The Purpose of This Task Order Is to Procure Storage and Stability for Antigens and Adjuvants From Prior Contracts for the Department of Health and Human Services Under Idiq 75A50122D000002 During…Glaxosmithkline, LLC · 75A50124F61010$7,790,728May 21, 2027in 6 monthsNC
The Purpose of This Requirement Is to Provide Medical Countermeasures (Mcms), Such As Vaccines and Adjuvants, for Pandemic Preparedness and Response or As Required in Response to a HHS DesignatedSanofi Vaccines US Inc. · 75A50124F61009$1,528,049May 21, 2027in 6 monthsPA
The Purpose of This Task Order Is to Procure Services for Storage and Stability Vaccine Bulk Lots From Prior Contracts for U.s. Department of Defense (DOD) Under Idiq Contract 75A50122D00002 During…Glaxosmithkline, LLC · 75A50124F61011$422,425May 21, 2027in 6 monthsNC
Ot Task Order 6 - DXR2Advanced Technology International · 75A50124F61006$100,000,000Jun 16, 2027in 6 monthsSC
Becton Dickenson: Multiplexed Respiratory Panel Tests for the Bd Veritor, the Bd Max, and the Bd Cor SystemsBecton, Dickinson and Company · 75A50121C00025$33,792,367Jun 30, 2027in 7 monthsMD
The Objective of This Contract Is to Develop a Second-Generation Assay for the Oraquick Ebola Rapid Antigen Test As a Sustainable, Enhanced Test Including Alternative Reagents (Antibody and Antigen)…Orasure Technologies Inc · 75A50122C00079$15,504,106Jun 30, 2027in 7 monthsPA
Execution of the Clinical Method Comparison Study and Regulatory Submission Required to Be Granted Clia-Waiver From the FDA for Febridx Response to Baa-23-100-Sol-00004Lumos Diagnostics, Inc · 75A50124C00051$9,183,030Jun 30, 2027in 7 monthsCA
Idiq Contract Management Support ActivitiesBattelle Memorial Institute · 75A50123F61001$155,532Jul 19, 2027in 8 monthsOH
Bio-Amt-2301: Idiq Contract Management Support ActivitiesMriglobal · 75A50123F61001$149,664Jul 19, 2027in 8 monthsMO
Bio-Amt-2301: Idiq Contract Management Support ActivitiesTexas Biomedical Research Institute · 75A50123F61001$145,615Jul 19, 2027in 8 monthsTX
Bio-Amt-2301: Idiq Contract Management Support ActivitiesLovelace Biomedical Research Institute · 75A50123F61001$100,283Jul 19, 2027in 8 monthsNM
The Overall Objective of This Contract Is to Assess the Ability of Auravax Therapeutics? (Auravax) Novel Mucosal Adjuvant Nanosting-002, Together With Influenza Live Attenuated Virus (Lav) Created…Auravax Therapeutics, Inc. · 75A50124C00054$749,999Jul 31, 2027in 8 monthsTX
Correlate of Protection (Cop) Studies to Support Development of the CAD3-Ebo-S (Sudan Virus) Candidate Vaccine.Battelle Memorial Institute · 75A50124F61005$11,705,345Aug 15, 2027in 8 monthsOH
To Develop Medical Countermeasures (Mcms) That Treat Antibiotic Resistant Infections.Vedanta Biosciences, Inc. · 75A50120C00177$99,146,088Aug 31, 2027in 9 monthsMA
Fill/Finish Adjuvant (AS03): Multi-Dose VialsGlaxosmithkline, LLC · 75A50126F61021$438,000Aug 31, 2027in 9 monthsNC
Ctpe Anthrax AV7909 Boost Evaluation and Antigen-Sparing Trial (Abeast)Icon Government and Public Health Solutions, Inc. · 75A50122F33004$10,320,205Sep 12, 2027in 9 monthsOH
The Contractor Shall Furnish All Necessary Services, Qualified Professional, Technical, and Administrative Personnel, Material, Equipment, and Facilities, Not Otherwise Provided by the Government…Biofire Defense LLC · 75A50122C00049$5,921,722Sep 22, 2027in 10 monthsUT
Testing Services to Support Translational Development of Next-Generation Botulism Therapeutic ProductsBattelle Memorial Institute · 75A50123F61002$6,279,015Sep 24, 2027in 10 monthsOH
Rtor-Chem-2206 Small Animal Model Development for Inhalational Chlorine ExposureNederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno · 75A50125F61002$3,720,333Sep 25, 2027in 10 monthsNot stated
Uk Health Security Agency - Base (Bio) - Idiq for Barda Biological Animal Model and Mcm DevelopmentUk Health Security Agency · 75A50123F61002$5,570,766Sep 28, 2027in 10 monthsNot stated
Development of CD388 As a Long-Lasting Prophylactic Anti-Viral Option for Protection Against the Health Impacts Caused by InfluenzaCidara Therapeutics Inc · 75A50125C00017$58,051,983Sep 29, 2027in 10 monthsCA
Wake Forest - Organ Tissue Equivalent (Ote) Platform for Vaccine TestingWake Forest University Health Sciences · 75A50124C00060$12,495,604Sep 29, 2027in 10 monthsNC
Manufacture and Stability Studies of Thimerosal-Free Pandemic Influenza Vaccine Multidose Vials (Mdvs)Sanofi Vaccines US Inc. · 75A50126F61014$6,018,839Sep 29, 2027in 10 monthsPA
This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (Marv) and Sudan Ebolavirus (Sudv) Disease.Albert B. Sabin Vaccine Institute, Inc. (the) · 75A50119C00055$145,378,689Sep 30, 2027in 10 monthsDC
The Development of a Multimodal Antibody Platform to Extend the Window of Immunotherapeutic Intervention. the Overall Objective of the Work Outlined in This Contract Is to Critically Evaluate the…Eitr Biologics, Inc. · 75A50123C00060$33,059,642Sep 30, 2027in 10 monthsCA
Repurposing of a Ferric Iron-Containing Heme B Complex (Panhematin) and a Sulfane Sulfur-Linked Dithiocarbamate (Disulfiram) As Potential Mcms Against Knockdown AgentsBattelle Memorial Institute · 75A50123F61002$8,384,176Sep 30, 2027in 10 monthsOH
Preflight Project Goal Is to Provide the Required Preflight Tests to Support the Avatar Flight Project for Its Artemis II Mission.President and Fellows of Harvard College · 75A50124F61002$3,196,979Sep 30, 2027in 10 monthsMA
The Overall Objective of This Contract Is to Prove a Methodology to Measure Dose in a Phantom Such That There Will Be Result NIST Traceable Dose Harmonization Among Institutions. Included in This…University of Wisconsin System · 75A50125C00009$449,084Sep 30, 2027in 10 monthsWI
Battelle IdiqBattelle Memorial Institute · 75A50124F61006$1,437,830Nov 4, 2027in 11 monthsOH
Radnuc 2201: Performance Verification of Institutional Radiation Dose Response for Acute Radiation Syndrome (Ars) Animal Models (Rodent, Rabbit, Minipig, or Non-Human Primate [nhp]).University of Maryland, Baltimore · 75A50123F61001$8,423,324Nov 28, 2027in 12 monthsMD
Chem 2207- Evaluation of Lyophilized Elapid Venom Acetylcholinesterase and Glycopyrrolate Versus Criterion Standard Treatment on Nerve Agent Mortality (Elevate Cst Study)Battelle Memorial Institute · 75A50126F61006$1,007,299Dec 15, 2027in 12 monthsOH
Lungpacer Medical USA Inc Lung-Protective Effects of Transvenous Diaphragm Activation in Patients With Ards Aoi #12: Mitigating Long-Term Effects (Mile) of Respiratory DistressLungpacer Medical USA Inc · 75A50123C00021$749,796Dec 15, 2027in 12 monthsPA
The Overall Objective of This Contract Is to Advance the Development of the Biofire Emerging Cov Panel As a Nucleic Acid Amplification Test Panel for Use on the Easy-to-Use Filmarray 2.0 and…Biofire Defense LLC · 75A50122C00073$15,958,896Dec 22, 2027in 13 monthsUT
Ot Task Order 5Advanced Technology International · 75A50123F61005$161,082,263Dec 31, 2027in 13 monthsSC
Venatorx Pharmaceuticals: New Antibiotics to Treat Drug-Resistant Gram-Negative Bacteria Including Public Health Pathogens.Basilea Pharmaceutica International Ltd, Allschwil · 75A50123C00050$45,192,122Dec 31, 2027in 13 monthsPA
Ace Rapid Molecular Test System for Point of Care (Poc) and in-Home Use With Saliva and Swab Samples for Covid-19 and BeyondAptitude Medical Systems Inc · 75A50123C00013$38,271,970Dec 31, 2027in 13 monthsMD
This Contract Is to Advance the Development of Romiplostim for Treatment of Hematopoietic Subsyndrome-Acute Radiation Syndrome (Hs-Ars) and Chemotherapy-Induced Thrombocytopenia (Cit) and a Drug…Amgen Inc. · 75A50119C00061$26,408,674Dec 31, 2027in 13 monthsCA
Clinical Development of OX390 (Atipamezole) As an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, Medetomidine, and Other ?2 AgonistsOrexo US Inc · 75A50125C00010$11,450,712Dec 31, 2027in 13 monthsNJ
Radnuc 2201: Performance Verification of Institutional Radiation Dose Response for Acute Radiation Syndrome (Ars) Animal Models (Rodent, Rabbit, Minipig, or Non-Human Primate [nhp]).University of Illinois · 75A50123F61001$6,286,605Feb 28, 2028in 15 monthsIL
Advance the Development of Potent, Cross-Reactive Multispecific Antibodies for the Prep Countermeasure of Covid-19 and Seasonal and Highly Pathogenic Avian Influenza.Modex Therapeutics, Inc · 75A50123C00056$103,516,903Feb 29, 2028in 15 monthsMA
Bio-Amt-2305: Refinement of Ferret Models for Improved Influenza Vaccines.Battelle Memorial Institute · 75A50125F61007$3,487,374Mar 25, 2028in 16 monthsOH
Rtor Bio-Amt-2312: Assessment of the Therapeutic Potential of Chloroquine and Oseltamivir in Two (2) Lethal Models of Influenza a H5N1Lovelace Biomedical Research Institute · 75A50126F61002$3,723,027Apr 25, 2028in 17 monthsNM

End dates are the current period of performance; options not yet exercised can extend them. An ending contract may be competed again, extended, or moved to another vehicle. BPA calls and orders shorter than six months are left out. Department of Defense contracts appear on USAspending.gov about 90 days after award.

Get new notices under NAICS 541714

New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.

Free. We use your email only for these alerts and never share it. Privacy